Blue Cross® and Blue Shield® of North Carolina (Blue Cross NC) | Healthy Blue + Medicare<sup>SM</sup> (HMO-POS D-SNP)

## Clinical Criteria Updates Effective May 28, 2025

**Summary**: The Pharmacy and Therapeutics (P&T) Committee approved the following *Clinical Criteria* applicable to the medical drug benefit for *Blue Cross NC*. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit *Clinical Criteria* to search for specific policies. For questions or additional information, use this **email**.

Please see the explanation/definition for each category of Clinical Criteria below:

- · New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number

Please share this notice with other members of your practice and office staff.

## Please note:

- The *Clinical Criteria* listed below applies only to the medical drug benefits contained within the member's medical plan. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Blue Cross NC only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
May 28, 2025	CC-0274	Bizengri (zenocutuzumab-zbco)	New
May 28, 2025	CC-0275	Ziihera (zanidatamab-hrii)	New
May 28, 2025	CC-0276	Tryngolza (olezarsen)	New
May 28, 2025	CC-0072	Vascular Endothelial Growth Factor (VEGF) Inhibitors	Revised
May 28, 2025	CC-0185	Oxlumo (lumasiran)	Revised

## https://bluecrossnc.com/providers/networks-programs/blue-medicare/healthy-blue-medicare

Blue Cross and Blue Shield of North Carolina Senior Health, DBA Blue Cross and Blue Shield of North Carolina, is an HMO-POS D-SNP plan with a Medicare contract and a NC State Medicaid Agency Contract (SMAC). Enrollment in Blue Cross and Blue Shield of North Carolina Senior Health depends upon contract renewal.

§, SM are marks of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross Blue Shield Association.

NCBCBS-CR-077233-25-CPN76946 February 2025

Effective Date	Clinical Criteria Number	Clinical Criteria Title	New or Revised
May 28, 2025	CC-0198	Relizorb (immobilized lipase) cartridge	Revised
May 28, 2025	CC-0256	Rivfloza (nedosiran)	Revised
May 28, 2025	CC-0042	Monoclonal Antibodies to Interleukin- 17	Revised
May 28, 2025	CC-0063	Ustekinumab Agents (Stelara, Selarsdi, Imuldosa, Pyzchiva, Otulfi, Wezlana, Yesintek)	Revised
May 28, 2025	CC-0058	Bynfezia Pen, Sandostatin, or Sandostatin LAR (Octreotide) / Octreotide Agents	Revised
May 28, 2025	CC-0130	Imfinzi (durvalumab)	Revised
May 28, 2025	CC-0094	Pemetrexed	Revised
May 28, 2025	CC-0003	Immunoglobulins	Revised